Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Van Echo

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Pharmacotherapy|March 1, 1985
Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicityJ Hornedo, D A Van Echo
Cancer Treatment Reports|September 1, 1978
Phase I study of neocarzinostatin in patients with acute leukemiaD A Van Echo, P H Wiernik
Cancer Clinical Trials|January 1, 1980
High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemiaD A Van Echo, P H Wiernik, J Aisner
Seminars in Oncology|April 1, 1989
The pharmacology of carboplatinD A Van Echo, M J Egorin, J Aisner
Cancer Treatment Reports|November 1, 1987
Phase II study of deoxydoxorubicin in patients with advanced liver cancerD J Perry, D A Van Echo, R Mick
Current Opinion in Oncology|December 1, 1989
Platinum compoundsC P Belani, D A Van Echo, J Aisner
Annals of Internal Medicine|April 1, 1973
Thoracic outlet syndrome, supraclavicular adenopathy, Hodgkin's diseaseD A Van Echo, E A Sickles, P H Wiernik
Cancer Treatment Reports|November 1, 1977
Vinblastine, 5-azacytidine, and VP-16-213 therapy for previously treated patients with acute nonlymphocytic leukemiaD A Van Echo, K M Lichtenfeld, P H Wiernik
Cancer Chemotherapy and Pharmacology|January 1, 1982
A phase I trial of continuous infusion VP16-213 (etoposide)J Aisner, D A Van Echo, M Whitacre, et al.
Cancer Treatment Reports|August 1, 1980
Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinomaD A Van Echo, S Markus, J Aisner, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Pharmacotherapy|March 1, 1985
Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicityJ Hornedo, D A Van Echo
Cancer Treatment Reports|September 1, 1978
Phase I study of neocarzinostatin in patients with acute leukemiaD A Van Echo, P H Wiernik
Cancer Clinical Trials|January 1, 1980
High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemiaD A Van Echo, P H Wiernik, J Aisner
Seminars in Oncology|April 1, 1989
The pharmacology of carboplatinD A Van Echo, M J Egorin, J Aisner
Cancer Treatment Reports|November 1, 1987
Phase II study of deoxydoxorubicin in patients with advanced liver cancerD J Perry, D A Van Echo, R Mick
Current Opinion in Oncology|December 1, 1989
Platinum compoundsC P Belani, D A Van Echo, J Aisner
Annals of Internal Medicine|April 1, 1973
Thoracic outlet syndrome, supraclavicular adenopathy, Hodgkin's diseaseD A Van Echo, E A Sickles, P H Wiernik
Cancer Treatment Reports|November 1, 1977
Vinblastine, 5-azacytidine, and VP-16-213 therapy for previously treated patients with acute nonlymphocytic leukemiaD A Van Echo, K M Lichtenfeld, P H Wiernik
Cancer Chemotherapy and Pharmacology|January 1, 1982
A phase I trial of continuous infusion VP16-213 (etoposide)J Aisner, D A Van Echo, M Whitacre, et al.
Cancer Treatment Reports|August 1, 1980
Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinomaD A Van Echo, S Markus, J Aisner, et al.
Pageof 8